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Objective: The combination of chondrocytes and mononuclear fraction (MNF) cells might solve the
expansion induced dedifferentiation problem of reimplanted cells in autologous chondrocytes implan-
tation as sufﬁcient cells would be available for direct, one-stage, implantation. Earlier in vitro work
already showed a positive stimulation of cartilage speciﬁc matrix production when chondrocytes and
MNF cells were combined. Therefore, this study aimed to evaluate cartilage regeneration using a one-
stage procedure combining MNF cells and primary chondrocytes for the treatment of focal cartilage
lesions in goats compared to microfracture treatment.
Design: Freshly created focal cartilage defects were treated with either a combination of chondrocytes
and MNF cells embedded in ﬁbrin glue or microfracture treatment. After 6 months follow-up local
regeneration as well as the general joint cartilage health were evaluated using validated scores and
biochemical assays.
Results: Macroscopic (P ¼ 0.015) scores for the cartilage surface at the treated defect were, after 6
months, signiﬁcantly higher for the chondrocyteMNF treatment compared to microfracture-treated
defects, but microscopic scores were not (P ¼ 0.067). The articulating cartilage showed more
(P ¼ 0.005) degeneration following microfracture treatment compared to chondrocyteMNF treatment.
Biochemical glycosaminoglycans (GAG) evaluation did not reveal differences between the treatments.
Both treatments had resulted in a slight to moderate cartilage degeneration at other locations in the joint.
Conclusion: In conclusion, treatment of focal articular cartilage lesions in goats using a combination of
MNF cells from bone marrow and unexpanded chondrocytes leads to better macroscopic regeneration
compared to microfracture, however needs further ﬁne-tuning to decrease the negative inﬂuence on
other joint compartments.
 2013 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Autologous chondrocyte implantation (ACI) is frequently used to
treat focal cartilage lesions in the knee. Due to the limited number
of cells that can be harvested from a biopsy, in vitro cell expansionto: D.B.F. Saris, Orthopaedic
dical Center, P.O. Box 85500,
33; Fax: 31-30-2510638.
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s Research Society International. Pfollowed by reimplantation of this precultured population is inev-
itable and considered to be the main drawback of this relatively
successful procedure. A combination of cells could be an alternative
for the expansion of harvested chondrocytes in ACI. When isolated
chondrocytes are directly combined with another cell type, which
also would improve the chondrogenic potential of reimplanted
cells, the whole procedure could be performed within one surgery
and the quality of regenerated cartilage improved.
The combination of cells derived from native tissue with other
cell types has recently gained attention to address currently
deﬁned challenges in regenerative medicine1. For example,
vascular endothelial cells and urothelial cells were both able to
differentiate adipose-derived stem cells into respectively theublished by Elsevier Ltd. All rights reserved.
J.E.J. Bekkers et al. / Osteoarthritis and Cartilage 21 (2013) 950e956 951osteogenic and urothelial lineage in order to enhance bone and
urothelial tissue engineering2,3. Articular cartilage matrix pro-
duction of expanded articular chondrocytes has been shown to be
positively inﬂuenced by primary chondrocytes and human adi-
pose-derived and embryonic stem cells in vitro4e6. In addition, the
chondrogenic phenotype of dedifferentiated chondrocytes was
improved when cocultured with mesenchymal stromal cells
(MSC)7e9. As these effects were also achieved when conditioned
medium and non-contact culture systems were used, the under-
lying mechanism could be explained by the communication be-
tween the cells through trophic factors5,8,10. The mononuclear
fraction (MNF) in bone marrow is a major source of trophic factors
and can easily be obtained in the timeframe of one surgery11.
Delivery of this bone marrow fraction to full-thickness cartilage
defects in horses showed good cartilage healing12. For this reason,
combination of primary isolated chondrocytes and MNF cells
could be the basis for a one-stage cell-based regenerative treat-
ment for focal articular cartilage defects. Therefore, this study
aimed to evaluate cartilage regeneration using a one-stage pro-
cedure combining MNF cells and primary chondrocytes for the




This experiment was approved by and conducted following the
guidelines of the animal care committee of the University of
Utrecht under number DEC 2011.III.03.026. A full-thickness chon-
dral lesion was created in the medial condyle of both knees in fe-
male Dutch milk goats. Per goat one defect was treated with a
combination of chondrocytes and MNF cells in ﬁbrin glue
(Beriplast, Nycomed, CSL Behring, The Netherlands) and the other
by microfracture. The animals were euthanized at 6 months after
surgery. Defect healing and the quality of articular cartilage in all
other compartments of the joint were determined using macro-
scopic, microscopic and biochemical analysis.
Animals
A total of nine adult Dutch milk goats (age 3e5 years old, weight
75  10 kg) were used in this study. The necessary number of an-
imal (n¼ 9) was determined by a power analysis (power of 0.90 and
an ɑ of 0.05) based on the estimated amount of glycosaminoglycans
(GAG) (32.2  2.3) at 6 months after cartilage surgery13.Once
arrived at the animal facility the goats were allowed to acclimatize
for at least 1 week before surgery. During follow-up food was
provided ad libitum and general health was assessed by the veter-
inarian of the institutional animal care facility. Up to 2 weeks after
surgery an additional health scoring system, focusing on wound
infection, limping and general activity, was scored.
Surgery
One day prior to surgery, the goats were weighed and prophy-
lactic pain medication was provided by a fentanyl skin patch.
Intravenous premedication (0.4 mg/kg detomidine hydrochloride
(Pﬁzer, The Netherlands) and a single dose of Augmentin (Glax-
oSmithKline, The Netherlands)) was followed by induction anes-
thesia using thiopental (6 mg/kg, Rhône Mérieux, France). During
surgery, anesthesiawasmaintained by a combination of midazolam
0.8 mg/kg (Abbott Laboratories, The Netherlands) and sufenta forte
0.007 mg/kg (ASTPharma, The Netherlands) and, if necessary, iso-
ﬂurane or propofol (Abbott Laboratories).Surgery was performed under aseptic conditions. Bone marrow
was obtained by needle aspiration from the iliac crest. For this a
Jamshidi needle was tapped into the iliac crest. Bone marrow was
aspirated using 20 ml sterile syringes and stored in heparin-coated
tubes. After this the whole bone marrow was spun down (300 g,
10 min) and the cell pellet diluted 50 times in red blood cell lysis
buffer (Sigma, The Netherlands) during 45 min. Following this the
remaining cells were spun down by centrifugation and washed
twice in phosphate buffered saline (PBS), thus producing the MNF
fraction.
A medial parapatellar approach was performed to expose the
medial femur condyle. After macroscopic scoring of the medial
cartilage surface, using the Mastbergen score14, a 5 mm cylindrical
chondral lesion was created in the central weight bearing region
using a hand-operated drill. A bone curette was used to debride
the remnants of articular cartilage and to create a stable defect
rim. The debrided defect cartilage was digested using a rapid-
digestion which resulted in chondrocytes with similar chondro-
genic potential, in terms of cartilage matrix formation, compared
to chondrocytes obtained after standard overnight isolation (data
not shown). For this, cartilage was cut into small pieces and
digested during 45 min in 2% collagenase type II solution
(Worthington, Lakewood, USA) in Dulbecco’s modiﬁed Eagle’s
medium (DMEM, GIBCO, USA) with penicillin/streptomycin
(100 U/ml/100 mg/ml, Invitrogen, The Netherlands) under
continuous shaking at 37C. Following digestion the collagen was
washed out by three washing steps. This digestion protocol
resulted in a digestion efﬁciency of 1.37  0.50  106 viable
chondrocytes per gram debrided tissue. Meanwhile, the debrided
defect was treated using the microfracture technique by creating
four holes through the subchondral bone using a 1.5 mm K-wire.
Microfracture treatment was conﬁrmed by the presence of blood
entering the defect from the drilled holes. Following this the knee
was closed in layers.
The other kneewas opened, the medial cartilage surface scored
and a chondral defect created using similar procedures as
described above. A mixture of 10% rapidly isolated chondrocytes
and 90% MNF cells were suspended in the ﬁbrinogen component
of Beriplast (Nycomed) at a ﬁnal concentration of 1  106 cells
per milliliter. The ﬁbrinogen component and thrombin compo-
nent of the Beriplastwere prepared for application following the
manufacturers’ protocol and injected into the cartilage defect.
After 5 min of gelation time the knee was ﬂexed 10 times to check
the stability of the graft into the defect and the knee was closed in
layers.
Direct full-weight bearing was allowed following surgery. The
animals were housed individually for a period of 24 h. Additional
pain medication and antibiotics were provided, based on the
judgment of the veterinarian, with approval of JEJB. The animals
were euthanized after 6 months using an overdose of pentobarbital
(Euthesate) and both hind legs explanted for further analysis.
Macroscopic cartilage evaluation
Soft tissues were removed from the explanted hind legs and
high-resolution pictures obtained from the medial femoral condyle
(MFC) and lateral femoral condyle (LFC) and tibial cartilage surfaces
(medial MTP, lateral LTP) and from the cartilage defect. Pictures
were coded for blinded scoring by two observers. The articular
cartilage of the medial and lateral tibia and femur as well as the
medial tibia cartilage that directly articulated with the treated
defect were scored using the macroscopic Mastbergen score14. The
Mastbergen score is a four-point scale ranging from a macroscop-
ically healthy and smooth cartilage surface (0 points) to cartilage
degeneration characterized by deep grooves and surrounding
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cartilage defect were scored using the International Cartilage
Repair Society (ICRS) macroscopic evaluation of cartilage repair
score15. This score (0e12 points scale) evaluates the macroscopic
cartilage repair on degree of defect repair and ﬁll, integration into
border zone and macroscopic appearance. The higher the score the
better the macroscopic cartilage repair. For both macroscopic
scoring systems the scores of the two observers were averaged.
Where individual items differed more than two points between
observers consensus was reached.
Microscopic cartilage evaluation
Microscopic evaluation was performed on osteochondral sam-
ples derived from the central weight bearing lateral femur and
tibia, the medial tibia cartilage that articulated with the defect and
from the posterior half of the defect. Samples were ﬁxed in 10%
buffered formalin for 48 h followed by a decalciﬁcation process
using Luthra’s solution (3.2% 11 M HCl, 10% formic acid in distilled
water). Following this samples were dehydrated by graded alcohol
series, immersed in xylene and embedded in parafﬁn. Sections
(5 mm) were stained with safranin-O (Merck, Germany) for GAG.
Counterstaining for nuclei and cytoplasm were performed with
respectively Weigert’s hematoxylin (Klinipath, The Netherlands)
and 0.4% fast green (Merck, Germany). The microscopic quality of
cartilage regeneration was assessed using the O’Driscoll score16,17.
This score (range 0e24 points) evaluates the regenerated cartilage
on the amount of Safranin-O staining in the matrix, cellular
morphology and clustering, the structural characteristics of the
tissue and degenerative changes in adjacent tissue. The higher the
score the better the microscopic cartilage regeneration. All other
osteochondral cartilage samples were evaluated using the Mankin
score which ranges from normal appearing articular cartilage (0
points) to tissue with complete disorganization, no matrix staining
and hypocellularity or cloning (14 points). Similar score processing
from the two observers was performed as with the macroscopic
scoring.
DNA and GAG content
Full-thickness articular cartilage was, if present, obtained from
the anterior part of the treated defect, the cartilage that articu-
lated with the defect and from the lateral weight bearing femur
and tibia cartilage. Samples were weighed and digested overnight
in papain (250 mg/ml papain (SigmaeAldrich) in 50 mM Ethyl-
enediaminetetraacetic acid (EDTA) and 5 mM L-cysteine) at 56C.
GAG content was determined using a dimethylmethylene blue
(DMMB) assay18 where the complexation of GAGs with DMMB
was measured spectophotometrically at 540 nm, using 595 nm as
a reference. Chondroitin sulfate (shark; SigmaeAldrich) was used
as a standard. Per sample, the DNA content was also determined
from the papain digest using a Picogreen DNA assay (Invitrogen)
in accordance with the manufacturer’s instructions.
Statistical analysis
All analyses were performed using SPSS version 15.0 (Chicago,
Illinois, USA). Outcome variables showed a normal distribution
tested by the KolmogoroveSmirnov test (P > 0.05) and equality of
variance as determined by the Levene’s test (P > 0.05). Differences
between the two treatments in macroscopic score, microscopic
score, GAG/gram tissue and GAG/DNA were tested using a paired
samples t-test. A P < 0.05 was considered statistically signiﬁcant.
All outcomes in graphs are presented as mean and 95% conﬁdenceinterval (CI). Biochemical GAG analysis is described using
mean  standard deviation.
Results
Animal health and follow-up
No signs of surgery-related complications like wound or joint
infection were observed after surgery and all animals were able to
move their joints and load their limbs without limitations. After 2
weeks no additional pain medication was provided. However, two
animals died. One animal died directly after surgery due to an
already existing, unrecognized, pulmonary infection. The other
goat was euthanized at 2 months follow-up due to progressive
weight loss and increased infection parameters which were, after
obduction, related to a large intra-abdominal cyst. The maximal
weight loss of the goats that reached 6 months follow-up was
4.5  3.0% compared to their preoperative weight.
Macroscopic evaluation
Peroperative macroscopic evaluation of the articular surfaces
showed superﬁcial ﬁbrillations that were related to the central
weight bearing cartilage of the MFC in three cases. Peroperative
macroscopic scores of femur cartilage surfaces did not differ
between the two groups receiving the treatments (P ¼ 0.62).
Post-treatment macroscopic scores of the articulating tibia carti-
lage were statistically signiﬁcantly (P ¼ 0.005) higher in the
microfracture-treated defects compared to the chondrocyteMNF-
treated defects. This indicates increased cartilage degeneration of
the articulating tibia cartilage following microfracture treatment of
a defect in the femur compared to chondrocyteMNF treatment.
Other joint locations (lateral tibia and femur cartilage and MFC) did
not show statistically signiﬁcant differences, however, the medial
compartment showed relatively high Mastbergen scores indicative
for moderate degeneration (Fig. 1). Overall, microfracture treat-
ment showed less defect ﬁll at 6 months compared to chon-
drocyteMNF treatment (Fig. 2). Also when the quality of
macroscopic cartilage regeneration was scored, the chon-
drocyteMNF treatment scored statistically signiﬁcantly (P ¼ 0.015)
higher compared to the microfracture-treated defects.
Microscopic evaluation
Mankin microscopic score for cartilage degeneration showed no
statistically signiﬁcant differences between the two treatments for
cartilage surfaces adjacent to the treated defects (Fig. 3). The
microscopic appearance of the regenerated tissue in the cartilage
defects treatedwith chondrocyteMNF appeared better compared to
the microfracture-treated defects although still incomplete defect
ﬁll was present after chondrocyteMNF treatment (Fig. 4). The
O’Driscoll score for the chondrocyteMNF-treated defects appeared
to be higher compared to the microfracture-treated defects,
although this did not fully reach statistical signiﬁcance (P ¼ 0.067).
The cartilage derived from the lateral compartment and cartilage
surrounding the defect showed slight cartilage degeneration while
those from the articulating medial tibia cartilage showed moderate
cartilage degeneration for both treatments (Fig. 3).
Biochemical evaluation
GAG production per gram of regenerated tissue did not show
statistically signiﬁcant differences between the two treatments
(25.61  14.95 mg GAG per gram tissue vs 23.51  6.82 mg GAG
per gram tissue for the microfracture and chondrocyteMNF
Fig. 1. Macroscopic scores 6 months after treatment. Macroscopic scores show no differences between the treatments at 6 months follow-up for the medial femur (MFC) and tibia
(MTP) surfaces, lateral femur (LFC) and tibia (LTP) surfaces and the articulating defect surface. At the treated defect site the chondrocyteMNF treatment showed a statistically
signiﬁcant (P ¼ 0.015) higher macroscopic ICRS score compared to the microfracture-treated defects. Scores are presented as boxplots.
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treatment (lateral femur 27.26  7.09 mg GAG per gram tissue,
lateral tibia 30.90  9.89 mg GAG per gram tissue, articulating
cartilage 28.34  10.11 mg GAG per gram tissue) did not result in
statistically signiﬁcant differences in GAGs per gram tissue
compared to chondrocyteMNF treatment (lateral femur
33.87  7.04 mg GAG per gram tissue, lateral tibia 25.04 11.76 mg
GAG per gram tissue, articulating cartilage 25.73  10.51 mg GAG
per gram tissue). Also for GAG content normalized to DNA content,
no difference between the treatments was observed (micro-
fracture: lateral femur 284  113 mg GAG/mg DNA, lateral tibia
390  332 mg GAG/mg DNA, articulating cartilage 462  278 mg
GAG/mg DNAvschondrocyteMNF: lateral femur 313144mg GAG/
mg DNA, lateral tibia 215  116 mg GAG/mg DNA, articulating
cartilage 416  208 mg GAG/mg DNA).
Discussion
This study shows that treatment of a freshly created cartilage
defect using a combination of MNF cells and primary chondrocytes,
mixed in ﬁbrin glue, leads to better macroscopic and a trend towardFig. 2. Representative examples of macroscopic repair after 6 months follow-up.
Macroscopic examples of defect ﬁll at 6 months follow-up for both treatments.
Microfracture treatment showed incomplete macroscopic defect ﬁll while the chon-
drocyteMNF treatment showed complete macroscopic ﬁll.better microscopic cartilage regeneration compared to micro-
fracture after 6 months follow-up in a goat model. Microfracture
treatment resulted in more macroscopic cartilage degeneration of
the directly opposing articulating tibia cartilage compared to
chondrocyteMNF treatment. After 6 months follow-up both treat-
ments had resulted in slight to moderate cartilage degeneration at
more remote locations in the joint. GAG and DNA content did not
differ between the two treatments at the regenerated defect
cartilage nor for cartilage samples from other locations in the joint.
Recent studies have shown that an incongruent cartilage surface
introduces high peak forces to the directly articulating cartilage
resulting in cartilage degeneration19. These effects were not only
observed after elevated implantation of osteochondral implants but
also after microfracture or due to untreated defects19e22. Inability
to restore the articular cartilage surface will make the partly re-
generated cartilage prone to damage as a non-continuous cartilage
surface has a higher tendency to deformwhich initiates accelerated
matrix damage and tissue loss23e25. Also, an incongruent cartilage
surface and incomplete defect ﬁll, which was mainly observed after
microfracture but also present in chondrocyteMNF-treated defects,
could have contributed to increased shear forces at the surface of
the articulating cartilage, thereby introducing cartilage degenera-
tion. This will initiate a cascade of matrix damage in the treated
joint compartment and eventually the contralateral compartment
and whole knee. For this reason, the incomplete defect ﬁll in this
study could have contributed to the slight to moderate degenera-
tion seen after 6 months follow-up in both treatments. In addition
to this, the bilateral approach could also have added to the slight
degeneration observed in both treatments at distant locations in
the joint. This is important asmost treatment failures or insufﬁcient
clinical improvement after cartilage therapy can eventually be
brought down to inadequate defect ﬁll and tissue regeneration26.
Short-term follow-up in this study at least shows better defect ﬁlls
as resembled by the higher macroscopic scores obtained after
chondrocyteMNF treatment. However, deﬁnite and more objective
conclusions could be observed after longer follow-up (12e24
months) which should be considered in future animal studies of
this approach.
The factor of success in the combination of chondrocytes, MNF
cells and ﬁbrin glue is difﬁcult to determine. Concentrated bone
marrow, derived from spinning down whole bone marrow aspi-
rates, showed better macroscopic and microscopic cartilage for-
mation compared tomicrofracture in an equinemodel12. Also, bone
Fig. 3. Microscopic scores 6 months after treatment. Microscopic scores for the articular cartilage surrounding and directly articulating with the treated defect and the lateral femur
(LFC) and tibia (LTP) surfaces for both the chondrocyteMNF (MNF) and microfracture (MF) treatment. No statistically signiﬁcant differences were observed in microscopic score
between the two treatments for the mentioned scores. However, a trend toward statistical signiﬁcance (P ¼ 0.067) was observed in microscopic score between chondrocyteMNF and
microfracture treatment at the treated defect. Scores are presented as boxplots.
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contributed to the repair of full-thickness focal lesions in mini-
pigs27. These studies show that the use of crude bone marrow cells
in cartilage repair has potential. However, results so far did not lead
to a clinical translation. If concentrated bone marrowwould be that
potent, in terms of cartilage regeneration, the added value of add-
ing chondrocytes could be questioned as well. Others already
showed the added value of adding cells from mesenchymal origin
to chondrocytes in culture8e10,28. These studies mainly evaluatedFig. 4. Best, mean and worst result of microscopic repair after 6 months follow-up. Cross-sec
the best, mean and worst result of both treatments showing incomplete defect ﬁll for the m
observed in some cases.the combinations of chondrocytes and MSCs and also show that
MSCs disappear during culture. This supports the idea of chon-
drocytes being responsible for tissue regeneration whereas added
cells rather steer this chondrogenic response by trophic factors.
MNF is speculated to be a potent source of trophic factors as well11.
How these trophic factors inﬂuence the fast digested chondrocytes
in this study is still subject to speculation, however growth factors
and stimulating cytokines could play a major role. The presented
study design is insufﬁcient to answer such mechanistic questions.tional slices perpendicular to the center of the treated defect at 6 months follow-up for
icrofracture treatment while nearly complete defect ﬁll following chondrocyteMNF was
J.E.J. Bekkers et al. / Osteoarthritis and Cartilage 21 (2013) 950e956 955Ideally, without taking animal ethics into account, another two
experimental groups should have been added to the study. One that
only consists of rapidly digested chondrocytes and another that
consists of only MNF cells in ﬁbrin glue. Additionally, the chon-
drocyteMNF group could use labeled cells in order to provide data
on cell faith and contribution in the newly formed cartilage.
The role of the carrier for the cell combinations should be
considered as well. A carrier of cells should provide stability during
the ﬁrst periods of cartilage regeneration and degrade inversely
related to the cartilage matrix that is being formed. For this study
we selected ﬁbrin glue as a carrier of cells because it is already
clinically applied, easy to handle and, most important, ﬁbrin seal-
ants facilitate cartilage regeneration and show a high (>90%)
chondrocyte viability29. New techniques also show that ﬁbrin glue
can be used as a vehicle for chondrocyte migration from minced
cartilage pieces30, while ﬁbrin glue could also be used as an
augmentation of microfracturing to provide stability to the bone
marrow entering the knee.
In conclusion, this study shows that the treatment of a focal
articular cartilage lesion using a combination of MNF cells from
bone marrow and unexpanded chondrocytes leads to statistical
signiﬁcantly higher macroscopic regeneration scores compared to
microfracture, however needs further ﬁne-tuning to improve
defect ﬁll and decrease the negative inﬂuence on other joint
compartments before clinical translation if safe and useful.
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